Technical analysis of Capricor Therapeutics, Inc. (CAPR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
Price Performance
| 1 month | +20.90% |
| 3 months | -69.84% |
| Year-to-date | -70.34% |
| 1 year | +40.79% |
| 3 years | +38.06% |
| 5 years | +70.18% |
52-Week Range
| 52-week High | $40.37 |
| 52-week Low | $2.96 |
| Avg Volume (90d) | 4.8M |
Technical Indicators
| SMA 50 | $10.49 |
| SMA 200 | $23.49 |
| Beta | 0.48 |
| 30-day Volatility (annualised) | 171.5% |
| Price vs SMA 50 | -18.4% |
| Price vs SMA 200 | -63.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.51 | |
| 2025-11 | $5.35 | -17.8% |
| 2025-12 | $28.86 | +439.4% |
| 2026-01 | $21.89 | -24.2% |
| 2026-02 | $27.93 | +27.6% |
| 2026-03 | $30.40 | +8.8% |
| 2026-04 | $33.58 | +10.5% |
| 2026-05 | $29.96 | -10.8% |
| 2026-06 | $24.08 | -19.6% |
| 2026-07 | $3.85 | -84.0% |
| 2026-08 | $9.91 | +157.4% |
| 2026-09 | $8.56 | -13.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $8.56 |
| Market Cap | $492M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.85 |
| EV / EBITDA | 0.52 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.37 |
| Current Ratio | 7.35 |